{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:51:26Z","timestamp":1785876686904,"version":"3.56.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006108\"","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001866"],"award-info":[{"award-number":["UL1TR001866"]}],"id":[{"id":"10.13039\/100006108\"","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857\"","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["Supported by a grant from Regeneron\/Sanofi"],"award-info":[{"award-number":["Supported by a grant from Regeneron\/Sanofi"]}],"id":[{"id":"10.13039\/100009857\"","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001866"],"award-info":[{"award-number":["UL1TR001866"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["Supported by a grant from Regeneron\/Sanofi"],"award-info":[{"award-number":["Supported by a grant from Regeneron\/Sanofi"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although alopecia areata (AA) greatly impacts patients\u2019 quality of life (QoL), there is no adequate validation of AA-targeted QoL surveys in clinical trials, hindering sufficient representation of patient-reported outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Better understanding of patient-reported outcomes may guide treatment goals and future clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a recent randomized controlled trial testing dupilumab in AA, patients were administered the Alopecia Areata Quality of Life Index (AA-QLI) and the Alopecia Areata Symptom Impact Scale (AASIS) surveys, specifically evaluating QoL in patients with AA. An in-depth analysis was performed to assess the utility of these questionnaires in this patient population, both at baseline and after treatment, and to determine a threshold for improved patient-reported outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>While AASIS correlated with baseline Severity of Alopecia Tool (SALT) scores and with therapeutic response, AA-QLI showed no correlation with AA severity before or after treatment. Itch strongly correlated with serum IgE levels across both surveys. Using various approaches to estimate a discriminative threshold for decreased impact of AA on QoL (by AASIS) following treatment, a SALT score of 20 points or less post-treatment was associated with improved patient-reported outcomes, including both AA-related symptoms and items within the daily activities\/feelings domain such as \u2018feeling sad\u2019 and \u2018feeling anxious or worry\u2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AASIS is better than AA-QLI to assess patient-reported outcomes. SALT \u2264 20 following treatment should be considered as a threshold for meaningful therapeutic outcome and as a clinical endpoint in future clinical trials for AA.<\/jats:p>\n                  <jats:p>What is already known about this topic? \u00a0Alopecia areata greatly compromises quality of life, and affected patients have increased prevalences of depression, anxiety and social phobia.Despite the significant negative impact of the disease on patients\u2019 wellbeing, validation of targeted questionnaires in alopecia areata is lacking, and a therapeutic response threshold for improved patient-reported outcomes is unknown.<\/jats:p>\n                  <jats:p>What does this study add? \u00a0This study investigated the utility of two different alopecia areata-targeted questionnaires \u2013 Alopecia Areata Quality of Life Index and Alopecia Areata Symptom Impact Scale (AASIS) \u2013 in a clinical trial setting.AASIS was found to correlate strongly with alopecia areata severity and clinical response.<\/jats:p>\n                  <jats:p>What are the clinical implications of this work? \u00a0Patients with \u2264 20% scalp hair loss after treatment reported improvement in multiple quality-of-life items, suggesting this as a meaningful therapeutic outcome that may guide clinicians and improve the development of future clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/bjd.21696","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T08:28:52Z","timestamp":1654244932000},"page":"539-547","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-3048","authenticated-orcid":false,"given":"Yael","family":"Renert-Yuval","sequence":"first","affiliation":[{"name":"Laboratory for Investigative Dermatology The Rockefeller University New York NY USA"},{"name":"Department of Dermatology, and Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-1976","authenticated-orcid":false,"given":"Joel","family":"Correa da Rosa","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology The Rockefeller University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garcet","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0497-8351","authenticated-orcid":false,"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering University of Mississippi Oxford MS USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bares","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Chima","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UC Davis Medical Center University of California Davis Health System Sacramento CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gilleaudeau","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology The Rockefeller University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sullivan-Whalen","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology The Rockefeller University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle K.","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-1778","authenticated-orcid":false,"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology The Rockefeller University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"2023010808115219000_bjd21696-bib-0001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000497166","article-title":"Psychological profile and quality of life of patients with alopecia areata","volume":"5","author":"Velez-Muniz","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"2023010808115219000_bjd21696-bib-0002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0003","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/jdv.15927","article-title":"\u2018The psychosocial burden of alopecia areata and androgenetica\u2019: a cross-sectional multicentre study among dermatological out-patients in 13 European countries","volume":"34","author":"Titeca","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808115219000_bjd21696-bib-0004","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjd.14497","article-title":"Alopecia areata and health-related quality of life: a systematic review and meta-analysis","volume":"175","author":"Rencz","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","article-title":"Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation","volume":"84","author":"Glickman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0006","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1111\/all.14814","article-title":"An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata","volume":"76","author":"Glickman","year":"2021","journal-title":"Allergy"},{"key":"2023010808115219000_bjd21696-bib-0007","first-page":"130","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0008","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"2023010808115219000_bjd21696-bib-0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5114\/ada.2019.82826","article-title":"Serum concentrations of selected proinflammatory cytokines in children with alopecia areata","volume":"36","author":"Tabara","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"2023010808115219000_bjd21696-bib-0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jaad.2019.11.064","article-title":"Bidirectional association between alopecia areata and major depressive disorder among probands and unaffected siblings: a nationwide population-based study","volume":"82","author":"Dai","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0011","first-page":"15","article-title":"Does skewing of cytokine production link alopecia areata and depression?","volume":"182","author":"Ohyama","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0012","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","article-title":"A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes","volume":"84","author":"Stein Gold","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0013","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2020.1839008","article-title":"Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials","author":"Reich","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2023010808115219000_bjd21696-bib-0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40257-021-00604-9","article-title":"Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes","volume":"22","author":"Silverberg","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0016","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"2023010808115219000_bjd21696-bib-0017","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1111\/j.1468-3083.2012.04629.x","article-title":"Quality of life in alopecia areata: a disease-specific questionnaire","volume":"27","author":"Fabbrocini","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808115219000_bjd21696-bib-0018","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","article-title":"The utility and validity of the Alopecia Areata Symptom Impact Scale in measuring disease-related symptoms and their effect on functioning","volume":"19","author":"Mendoza","year":"2018","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2023010808115219000_bjd21696-bib-0019","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1038\/jidsymp.2013.19","article-title":"Development of the Alopecia Areata Symptom Impact Scale","volume":"16","author":"Mendoza","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2023010808115219000_bjd21696-bib-0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/ijt.ijt_112_20","article-title":"Alopecia Areata-Quality of Life Index questionnaire (reliability and validity of the Persian version) in comparison to Dermatology Life Quality Index","volume":"12","author":"Nasimi","year":"2020","journal-title":"Int J Trichol"},{"key":"2023010808115219000_bjd21696-bib-0021","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/09546634.2019.1654068","article-title":"Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata","volume":"32","author":"Lai","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2023010808115219000_bjd21696-bib-0022","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0023","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15044","article-title":"Superficial cryotherapy using dimethyl ether and propane mixture versus microneedling in the treatment of alopecia areata: a prospective single-blinded randomized clinical trial","volume":"34","author":"Aboeldahab","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023010808115219000_bjd21696-bib-0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLOS Med"},{"key":"2023010808115219000_bjd21696-bib-0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/5584_2020_548","article-title":"Pruritus characteristics in severe atopic dermatitis in adult patients","volume":"1289","author":"Jaworek","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"2023010808115219000_bjd21696-bib-0026","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"key":"2023010808115219000_bjd21696-bib-0027","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.688999","article-title":"Pruritus, allergy and autoimmunity: paving the way for an integrated understanding of psychodermatological diseases?","volume":"2","author":"Ferreira","year":"2021","journal-title":"Front Allergy"},{"key":"2023010808115219000_bjd21696-bib-0028","doi-asserted-by":"crossref","first-page":"106","DOI":"10.23736\/S0392-0488.18.06177-1","article-title":"Patient-reported outcomes in dermatology research and practice","volume":"154","author":"Austin","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"2023010808115219000_bjd21696-bib-0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102711","article-title":"Resident human dermal \u03b3\u03b4T-cells operate as stress-sentinels: lessons from the hair follicle","volume":"124","author":"Uchida","year":"2021","journal-title":"J Autoimmun"},{"key":"2023010808115219000_bjd21696-bib-0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/09546634.2020.1782820","article-title":"Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic","volume":"33","author":"Kutlu","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2023010808115219000_bjd21696-bib-0031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808115219000_bjd21696-bib-0032","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamadermatol.2019.3717","article-title":"Association between quality of life and improvement in psoriasis severity and extent in pediatric patients","volume":"156","author":"Bruins","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023010808115219000_bjd21696-bib-0033","article-title":"Features associated with quality of life impairment in hidradenitis suppurativa patients","volume":"8","author":"Schneider-Burrus","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023010808115219000_bjd21696-bib-0034","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(18)32987-8","article-title":"JAK inhibitors and alopecia areata","volume":"393","author":"Gilhar","year":"2019","journal-title":"Lancet"},{"key":"2023010808115219000_bjd21696-bib-0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.21696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.21696","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/4\/539\/48529818\/bjd0539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/4\/539\/48529818\/bjd0539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:13:30Z","timestamp":1676384010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/4\/539\/6966341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.21696","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"2022-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}